PDCD1 and glioblastoma: Although anti-PD1/PD-L1 immunotherapy shows durable response in other types of malignancies, its efficacy is limited to approximately 10% of GBM patients (11–13), thus highlighting the need for more effective and novel approaches, including the combination of additional IC inhibitors (ICIs) to target several IC pathways simultaneously.